Jasper Therapeutics, Inc., (JSPR): Price and Financial Metrics
GET POWR RATINGS... FREE!
JSPR Stock Price Chart Interactive Chart >
JSPR Price/Volume Stats
| Current price | $3.14 | 52-week high | $18.88 |
| Prev. close | $3.00 | 52-week low | $2.45 |
| Day low | $3.02 | Volume | 16,000 |
| Day high | $3.43 | Avg. volume | 75,663 |
| 50-day MA | $3.17 | Dividend yield | N/A |
| 200-day MA | $6.77 | Market Cap | 118.92M |
Jasper Therapeutics, Inc., (JSPR) Company Bio
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Latest JSPR News From Around the Web
Below are the latest news stories about Jasper Therapeutics Inc that investors may wish to consider to help them evaluate JSPR as an investment opportunity.
Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRJSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study17 of 17 subjects achieved successful engraftment with neutrophil recovery12 of 15 subjects with measurable residual disease (MRD) at screening achieved clearance of MRD REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic |
Grace Capital Buys Vanguard Consumer Discretionary ETF, Tesla Inc, Jasper Therapeutics Inc, ...Investment company Grace Capital (Current Portfolio) buys Vanguard Consumer Discretionary ETF, Tesla Inc, Jasper Therapeutics Inc, Alphabet Inc, Blueknight Energy Partners LP, sells Vanguard Real Estate Index Fund ETF, Vanguard Health Care ETF, SPDR Bloomberg High Yield Bond ETF, SPDR Blackstone Senior Loan ETF, iShares TIPS Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Grace Capital. |
Jasper Therapeutics (JSPR) Receives a Buy from William BlairIn a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $19.00. The company's shares closed last Wednesday at $8.22, close to its 52-week low of $7.03. According to TipRanks.com, Phipps is a 2-star analyst with an average return of 1.2% and a 39.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Actinium Pharmaceuticals, and Atara Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jasper Therapeutics with a $18.50 average price target. |
Billionaire Ken Griffin Goes Big on These 3 “Strong Buy” StocksThe market’s legendary investors built their names, and their fortunes, on success, the paths they followed were as varied and interesting as in any human endeavor. And one of the best such stories for market success is that of Ken Griffin, whose firm Citadel manages approximately $39 billion in total assets. Griffin founded Citadel in 1990, and last year the firm’s funds brought in an average return of 24%. Griffin himself has seen his personal net worth grow to $16 billion. |
Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual MeetingJSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical benefit REDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following tar |
JSPR Price Returns
| 1-mo | 16.30% |
| 3-mo | -16.04% |
| 6-mo | -59.95% |
| 1-year | -68.31% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -60.00% |
| 2021 | -21.58% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...